Gary R. Cott

Mechanisms of long COVID and the path toward therapeutics

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

Lack of Benefit of Methotrexate in Severe, Steroid-Dependent Asthma

Stimulation of net active ion transport across alveolar type II cell monolayers